Physicians and patients are increasingly seeking improved control and comfort from drug delivery systems designed to allow self-administration of injectable medicines.
Glide has combined solid dose drug formulation expertise with advanced ergonomics and engineering to develop its solid dose injector system – the SDI®, designed to make self-administration of injectable drugs simple and safe. Patients find the SDI® easy to use and, in Human Factor studies, overwhelmingly prefer SDI® to needle and syringe-based delivery. Glide’s SDI® has the potential to improve the treatment experience of both patients and their carers.
The reusable SDI® actuator delivers the drug subcutaneously as a solid dose, in a fraction of a second. Once in the subcutaneous tissue the solid formulation dissolves within minutes. Preclinical studies show that drug pharmacokinetics are equivalent to those seen with conventional liquid delivery by needle and syringe. With the SDI®, however, there is no needle and consequently there is no danger of needle-stick injury after use.
Glide’s pipeline includes the therapeutic peptides octreotide, teriparatide and exenatide – all of which are normally self-administered by patients. Glide’s octreotide SDI® programme successfully completed a phase I clinical trial in 2016.
The Glide SDI® comprises two main components:
All components, apart from the reusable actuator, are sterile.
The core of Glide’s SDI® technology is a tiny, solid dose of active pharmaceutical supplied within a disposable plastic cassette. The cassette is supplied in a holder within sterile packaging.
Before use the cassette is inserted into the actuator, which is primed by the action of pressing the loaded cassette against the skin. It then automatically triggers and delivers the solid dose formulation through the skin and into the subcutaneous tissue.